News & Press
GeNeuro announces the results of the GNC-501 in post-COVID-19 syndrome
Geneva, Switzerland, June 28, 2024 – 7:00 am CEST – The GNC-501 clinical trial is a Phase 2 study in patients suffering from post-COVID-19 neuropsychiatric syndromes, testing temelimab against placebo. The study enrolled over 200 patients in Switzerland, Spain and Italy who had tested positive for HERV-W ENV. The top-line results from this study show that treated patients had no clinically meaningful improvement compared to placebo on the primary endpoint measuring the improvement of fatigue with the PROMIS SF7a test. The majority of secondary endpoints did not show an effect either. The treatment was very well tolerated and safe, consistent with previous clinical trials in other indications.
GeNeuro Announces Approval of all Resolutions Proposed at 12 June 2024 Annual General Meeting
GeNeuro Announces Approval of all Resolutions
Proposed at 2024 Annual General Meeting
Geneva, Switzerland, June 14, 2024 – 6:30pm CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe neuropsychiatric consequences of COVID-19 (post-COVID or Long-COVID), today announced that its shareholders have approved all resolutions proposed at its Annual General Meeting (AGM) of 12 June 2024.
/https://geneuro.ch/wp-content/uploads/GeNeuro_AGM_14062024-EN.pdf
GeNeuro Announces Last Patient Last Visit in its Post-COVID Trial and Confirms Top-Line Results by End of June 2024
Geneva, Switzerland, May 16, 2024 – 8.00 am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing therapies for patients with neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and Post- Acute Sequelae of COVID-19 (PASC, long-COVID or post-COVID), today announced that the last patient enrolled in the GNC-501 trial of temelimab against post-COVID has now completed the study.
GeNeuro publishes its 2023 Universal Registration Document
Geneva, Switzerland, May 2, 2024 – 6:00pm CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing novel treatments for neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe consequences of COVID- 19, (PASC, post-COVID or Long-COVID), publishes its 2023 Universal Registration Document, in English, which has been filed on April 30, 2024 with the “Autorité des Marchés Financiers (AMF)”.
GeNeuro Reports 2023 Full-Year Results and Provides Corporate Update
Geneva, Switzerland, April 30, 2024 – 6.30pm CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company focused on halting the progression of neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the post-acute sequelae of COVID-19 (PASC, long COVID or post-COVID), reported today its full-year results for the year ended December 31, 2023, and provided a corporate update.
GeNeuro Announces Approval of all Resolutions Proposed at March 18, 2024, Extraordinary General Meeting
Geneva, Switzerland, March 20, 2024 – 6:30pm CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe neuropsychiatric consequences of COVID-19 (post-COVID or Long-COVID), today announced that its shareholders have approved all resolutions proposed at its Extraordinary General Meeting (EGM) of March 18, 2024.
GeNeuro annonce la mise à disposition d’un prospectus à l’occasion de l’admission d’actions nouvelles sur Euronext Paris
Genève, Suisse, le 2 février 2024 – 20:00 CEST – GeNeuro (Euronext Paris : CH0308403085 – GNRO) (la « Société »), société biopharmaceutique dont l’objectif est l’arrêt de la progression des maladies neurodégénératives et auto-immunes telles que la sclérose en plaques (SEP), la sclérose latérale amyotrophique (SLA) et les séquelles post-aigües du COVID-19 (PASC, COVID long ou post-COVID), annonce que l’Autorité des marchés financiers (l’ « AMF ») a approuvé le 2 février 2024 un prospectus d’admission sous le numéro 24-016 (le « Prospectus ») dans le cadre de l’admission aux négociations sur le marché règlementé d’Euronext Paris de 4.666.901 actions nouvelles ordinaires au porteur de la Société émises à la suite d’une augmentation de capital de 5 millions d’euros avec suppression des droits préférentiels de souscription réalisée dans le cadre (i) d’un placement privé international réservé à des investisseurs spécialisés et stratégiques de 4.666.901 actions nouvelles ordinaires au porteur (le « Placement Privé International ») et (ii) d’une offre au public séparée destinée aux investisseurs particuliers via la plateforme PrimaryBid uniquement en France de 95.004 nouvelles actions ordinaires au porteur (avec le Placement Privé International, l’ « Offre »).
https://geneuro.ch/data/news/Geneuro-CP-norme-de-mise-a-dispo-prospectus-02.02.2024.pdf
GeNeuro announces a successful €5 million private placement
Geneva, Switzerland, February 2, 2024 – 08:00 CET – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company focused on stopping the progression of neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and Post-Acute Sequelae of COVID-19 (PASC, long-COVID or post-COVID), today announced the successful completion of a €5 million capital increase with cancellation of the preferential subscription rights through an international private placement reserved for specialized or strategic investors of (the “Private Placement”) 4,666,901 new ordinary bearer shares of GeNeuro and through a public offering for retail investors in France via the PrimaryBid platform (the “PrimaryBid Offer”, and together with the Private Placement, the “Offering”) of 95,004 new ordinary bearer shares of GeNeuro. All new ordinary shares have a par value of CHF 0.05 each (the “New Shares”).
https://geneuro.ch/data/news/PR-GeNeuro-Closes-Financing-ENG-02.02.2024.pdf
GeNeuro launches an offering with a commitment to subscribe by existing shareholders and announces its cash position at December 31, 2023
Geneva, Switzerland, February 1, 2024– 5.45pm CET – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company focused on stopping the progression of neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and Post-Acute Sequelae of COVID-19 (PASC, long-COVID or post-COVID), today announces the launch of a private placement of ordinary shares to be issued by the Company, in connection with a share capital increase without preferential subscription rights of an indicative amount of €5 million by way of a private placement reserved to certain qualified investors, with an accelerated book-building; the offering will also include a public offering for retail investors, in France only through the PrimaryBid platform. The Company also announces its 2023 year-end cash position.
https://geneuro.ch/data/news/PR-GeNeuro-Announces-YE-2023-Cash-and-Launches-Financing-eng.pdf
GeNeuro names Anke Post as Chief Medical Officer, following retirement of David Leppert who becomes a consultant to GeNeuro
Geneva, Switzerland, January 5, 2024 – 6pm CET – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company focused on stopping the progression of neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and Post-Acute Sequelae of COVID-19 (PASC, long-COVID or post-COVID), today announces the appointment of Anke Post, MD, PhD as Chief Medical Officer, effective immediately, as David Leppert, MD, retires.
https://geneuro.ch/data/news/GeNeuro-PR-A.-Post-CMO-appointment-EN-Jan.-5-2024.pdf
Independent Data Monitoring Committee recommends continuing the trial evaluating temelimab in Long COVID without any modifications
Geneva, Switzerland, December 11th, 2023 – 8:00 AM CET – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and Post-Acute Sequelae of COVID-19 (PASC, Long-COVID or post-COVID), today announced that, as planned in the Study Protocol, the Independent Data Monitoring Committee met to review the unblinded safety and efficacy data of the first 90 patients after three months of treatment.
https://geneuro.com/data/news/PR-GeNeuro-12112023-IDMC-EN-final.pdf
GeNeuro announces completion of recruitment of its long-COVID Phase 2 trial and confirms top-line results for June 2024
Geneva, Switzerland, November 28, 2023 – 8:00 AM CET – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and Post-Acute Sequelae of COVID-19 (PASC, long-COVID or post-COVID), today announced the completion of the recruitment of its Phase 2 trial evaluating temelimab against long-COVID.
https://geneuro.com/data/news/PR-GeNeuro-11282023-LPFV-EN.pdf